Bioasis Technologies (FRA:107) EBIT : €-2.32 Mil (TTM As of Nov. 2022)

View and export this data going back to 2017. Start your Free Trial

What is Bioasis Technologies EBIT?

Bioasis Technologies's earnings before interest and taxes (EBIT) for the three months ended in Nov. 2022 was €-0.56 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Nov. 2022 was €-2.32 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Bioasis Technologies's annualized ROC % for the quarter that ended in Nov. 2022 was -84.91%. Bioasis Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2022 was %.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Bioasis Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Nov. 2022 was -114.22%.

Bioasis Technologies EBIT Historical Data

The historical data trend for Bioasis Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bioasis Technologies EBIT Chart

Bioasis Technologies Annual Data

Trend

Feb13

Feb14

Feb15

Feb16

Feb17

Feb18

Feb19

Feb20

Feb21

Feb22

EBIT

Get a 7-Day Free Trial

-3.40

-3.24

-3.18

0.25

-2.49

Bioasis Technologies Quarterly Data
	Feb18	May18	Aug18	Nov18	Feb19	May19	Aug19	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22
EBIT	Get a 7-Day Free Trial															-0.72	-1.11	0.01	-0.66	-0.56

Competitive Comparison of Bioasis Technologies's EBIT

For the Biotechnology subindustry, Bioasis Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bioasis Technologies's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Bioasis Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Bioasis Technologies's EV-to-EBIT falls into.

Bioasis Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Nov. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was €-2.32 Mil.

Bioasis Technologies (FRA:107) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Bioasis Technologies's annualized ROC % for the quarter that ended in Nov. 2022 is calculated as:

	ROC % (Q: Nov. 2022 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Aug. 2022 )	+	Invested Capital (Q: Nov. 2022 ))	/ count )
=	-2.04 * ( 1 - 0% )	/	( (2.528	+	2.277)	/ 2 )
=	-2.04	/	2.4025
=	-84.91 %

where

	Invested Capital		(Q: Aug. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.775	-	1.177	-	( 0.434	-	max(0, 2.624	-	0.694	+	0.434	))
=	2.528

	Invested Capital		(Q: Nov. 2022 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1.285	-	1.355	-	( 0.114	-	max(0, 2.627	-	0.28	+	0.114	))
=	2.277

Note: The Operating Income data used here is four times the quarterly (Nov. 2022) data.

2. Joel Greenblatt's definition of Return on Capital:

Bioasis Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Nov. 2022 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Nov. 2022 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Aug. 2022		Q: Nov. 2022
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-2.256	/	( ( (0 + max(-1.218, 0))	+	(0 + max(-1.368, 0)) )	/	2 )
=	-2.256	/	( ( 0	+	0 )	/	2 )
=	-2.256	/	0
=	%

where Working Capital is:

	Working Capital		(Q: Aug. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.014	+	0	+	0.246)	-	(1.177	+	0.301	+	0)
=	-1.218

	Working Capital		(Q: Nov. 2022 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0.01	+	0	+	0.156)	-	(1.355	+	0.179	+	0)
=	-1.368

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Nov. 2022) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Bioasis Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Nov. 2022 )
	=	-2.321	/	2.032
	=	-114.22 %

Bioasis Technologies EBIT Related Terms

Thank you for viewing the detailed overview of Bioasis Technologies's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Bioasis Technologies (FRA:107) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Bioasis Technologies Inc (FRA:107) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

157 Church Street, 19th Floor, New Haven, CT, USA, 06510

Website

https://www.bioasis.us

Bioasis Technologies Inc is a development stage biopharmaceutical company. It is engaged in the research and development of products for the diagnosis and treatment of neurological diseases and disorders. The company has worked on a blood-brain barrier program and studies disorders in the brain. The company's xB3 program describes its proprietary carrier, for the delivery of therapeutics across the blood-brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The company's in-house development programs are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders.

Bioasis Technologies (FRA:107) Headlines

No Headlines